CIK 0001437402 · Large accelerated filer
ARDELYX, INC.
Sign in to watch- Ticker
- ARDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 510-745-7047
- Business address
- 34175 ARDENWOOD BLVD., FREMONT, CA, 94555
- Former names
- NTERYX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $486,197
- in 8 filings
Net −$486,197. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- RAAB MICHAEL −$226K President & CEO sold 3% of stake
- Bishop John E −$76K See Remarks sold 6% of stake
- Brady James Parker −$58K Chief Human Resources Officer sold 6% of stake
- Williams Laura A −$41K Chief Patient Officer sold 3% of stake
- Foster Eric Duane −$33K Chief Commercial Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-25 | Kelliher Mike See Remarks | Grant or award | +136,680 | 296,680 | ||
| 2025-02-25 | Kelliher Mike See Remarks | Grant or award · Stock Option (Right to Buy) | +205,019 | 205,019 | ||
| 2025-02-25 | GRAMMER ELIZABETH A See Remarks | Grant or award | +136,680 | 317,723 | ||
| 2025-02-25 | GRAMMER ELIZABETH A See Remarks | Grant or award · Stock Option (Right to Buy) | +205,019 | 205,019 | ||
| 2025-02-25 | Foster Eric Duane Chief Commercial Officer | Grant or award | +136,680 | 316,680 | ||
| 2025-02-25 | Foster Eric Duane Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +205,019 | 205,019 | ||
| 2025-02-24 | MOTT DAVID M Director | Purchase | +77,729 | $5.00 | $389K | 2,015,494 |
| 2025-02-20 | Williams Laura A Chief Medical Officer | Sale | −4,941 | $5.62 | $28K | 303,804 |
| 2025-02-20 | Renz Justin A Chief Financial Officer | Sale | −5,171 | $5.62 | $29K | 285,968 |
| 2025-02-20 | RAAB MICHAEL President & CEO | Sale | −22,964 | $5.62 | $129K | 1,085,755 |
| 2025-02-20 | GRAMMER ELIZABETH A See Remarks | Sale | −4,291 | $5.62 | $24K | 181,043 |
| 2025-01-31 | RAAB MICHAEL President & CEO | Option exercise 10b5-1 | +20,833 | $0.99 | $21K | 1,150,385 |
| 2025-01-31 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −41,666 | $5.36 | $223K | 1,108,719 |
| 2025-01-31 | RAAB MICHAEL President & CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,833 | 478,334 | ||
| 2025-01-21 | MOTT DAVID M Director | Purchase | +199,000 | $4.99 | $993K | 1,937,765 |
| 2025-01-16 | Rodgers Richard J Director | Option exercise | +100,000 | $0.55 | $55K | 350,524 |
| 2025-01-16 | Rodgers Richard J Director | Option exercise · Stock Option (Right to Buy) | −100,000 | 0 | ||
| 2025-01-07 | RAAB MICHAEL President & CEO | Option exercise 10b5-1 | +20,833 | $0.99 | $21K | 1,171,218 |
| 2025-01-07 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −41,666 | $5.31 | $221K | 1,129,552 |
| 2025-01-07 | RAAB MICHAEL President & CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,833 | 499,167 |
Page 10 of 11 · 206 trades